<?xml version="1.0" encoding="utf-8" standalone="yes"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
  <channel>
    <title>生物制药 on AI内参</title>
    <link>https://www.neican.ai/tags/%E7%94%9F%E7%89%A9%E5%88%B6%E8%8D%AF/</link>
    <description>Recent content in 生物制药 on AI内参</description>
    <generator>Hugo</generator>
    <language>zh-cn</language>
    <lastBuildDate>Tue, 21 Jul 2026 18:10:13 +0800</lastBuildDate>
    <atom:link href="https://www.neican.ai/tags/%E7%94%9F%E7%89%A9%E5%88%B6%E8%8D%AF/index.xml" rel="self" type="application/rss+xml" />
    <item>
      <title>制药巨头的“数字炼金术”：BMS押注英伟达算力</title>
      <link>https://www.neican.ai/insights/bms-20260721181013305-2/</link>
      <pubDate>Tue, 21 Jul 2026 18:10:13 +0800</pubDate>
      <guid>https://www.neican.ai/insights/bms-20260721181013305-2/</guid>
      <description>百时美施贵宝采购英伟达最新算力架构，意在通过AI加速药物研发流程。此举凸显了算力作为生物医药核心资产的商业价值，标志着制药行业从传统实验室研发向算力驱动的工业化范式转型。</description>
    </item>
  </channel>
</rss>
